1. Labs AI is live: HIMS's first AI care agent spots patterns across 130+ biomarkers and produces personalised in-depth

The data flywheel has moved from collecting data to creating value, and switching costs keep rising. 2. The shares surged 10.2% on Friday to $28.27, jumping from $25.68 in a single day as bulls piled in ahead of the results. Q1 results come out on 11 May after the close, with the options market pricing in a move of about 14.8%. Deutsche Bank had just cut its target price, yet the shares still rose: the market's bet on a beat is outweighing the bear narrative. 3. The annual report confirms that more than 70% of US revenue comes from personalised products, with most revenue from outside GLP-1. Even if GLP-1 compounded drugs disappeared entirely, the core business is much sturdier than the market perceives.